ASTRAZENECA ANNUAL REVIEW 2006 CONSOLIDATED INCOME STATEMENT FOR THE YEAR ENDED 31 DECEMBER 2006 2005 2004 $m $m $m Sales 26,475 23,950 21,426 Cost of sales 5,559 5,356 5,193 Distribution costs 226 211 177 Research and development 3,902 3,379 3,467 Selling, general and administrative costs 9,096 8,695 8,268 Other operating income and expense 524 193 226 Operating pro t 8,216 6,502 4,547 Pro t on sale of interest in joint venture 219 Finance income 888 665 532 Finance expense 561 500 454 Pro t before tax 8,543 6,667 4,844 Taxation 2,480 1,943 1,161 Pro t for the period 6,063 4,724 3,683 Attributable to: Equity holders of the Company 6,043 4,706 3,664 Minority interests 20 18 19 Basic earnings per $0.25 Ordinary Share $3.86 $2.91 $2.18 Diluted earnings per $0.25 Ordinary Share $3.85 $2.91 $2.18 Weighted average number of Ordinary Shares in issue millions 1,564 1,617 1,673 Diluted weighted average number of Ordinary Shares in issue millions 1,570 1,618 1,675 Dividends declared and paid in the period 2,217 1,676 1,408 All activities were in respect of continuing operations.
CONSOLIDATED STATEMENT OF RECOGNISED INCOME AND EXPENSE FOR THE YEAR ENDED 31 DECEMBER 2006 2005 2004 $m $m $m Pro t for the period 6,063 4,724 3,683 Foreign exchange and other adjustments on consolidation 922 1,052 744 Available for sale losses gains taken to equity 20 10 31 Actuarial loss for the period 108 35 179 Tax on items taken directly to reserves 137 25 416 931 1,122 1,012 Total recognised income and expense for the period 6,994 3,602 4,695 Attributable to: Equity holders of the Company 6,970 3,595 4,690 Minority interests 24 7 5 Tax on items taken directly to reserves in 2004 includes a credit of $357m in respect of foreign exchange losses in 2000.
$m means millions of US dollars.
